{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:53Z","timestamp":1786993493327,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtct.2024.04.014","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T23:25:28Z","timestamp":1713655528000},"page":"681.e1-681.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-0113","authenticated-orcid":false,"given":"Ivan","family":"Pasic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy Alfaro","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Remberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Gerbitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-5699","authenticated-orcid":false,"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-3609","authenticated-orcid":false,"given":"Arjun Datt","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-3117","authenticated-orcid":false,"given":"Igor","family":"Novitzky-Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jtct.2024.04.014_bib0001","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.04.014_bib0002","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0003","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.014_bib0004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.04.014_bib0005","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes\u2014long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.014_bib0006","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.014_bib0007","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ejh.14041","article-title":"Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission","volume":"111","author":"Alfaro Moya","year":"2023","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.014_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/bmt.2011.88","article-title":"Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike","volume":"47","author":"Danylesko","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2024.04.014_bib0009","first-page":"5470","article-title":"Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients","volume":"60","author":"Westerhof","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2024.04.014_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.591363","article-title":"Long-term outcomes of treosulfan- vs. busulfan-based conditioning regimen for patients with myelodysplastic syndrome and acute myeloid leukemia before hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0011","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00280-007-0669-3","article-title":"Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients","volume":"62","author":"Munkelt","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.jtct.2024.04.014_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002800050791","article-title":"Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors","volume":"42","author":"Hilger","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2024.04.014_bib0013","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1021\/jm00300a034","article-title":"Epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. Preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate","volume":"13","author":"Feit","year":"1970","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.jtct.2024.04.014_bib0014","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40262-018-0647-4","article-title":"Treosulfan pharmacokinetics and its variability in pediatric and adult patients undergoing conditioning prior to hematopoietic stem cell transplantation: current state of the art, in-depth analysis, and perspectives","volume":"57","author":"Roma\u0144ski","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0015","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s43440-020-00115-0","article-title":"Population pharmacokinetic approach for evaluation of treosulfan and its active monoepoxide disposition in plasma and brain on the basis of a rat model","volume":"72","author":"Danielak","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.014_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exphem.2005.09.015","article-title":"Myeloablative and immunosuppressive properties of treosulfan in mice","volume":"34","author":"Sj\u00f6\u00f6","year":"2006","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.04.014_bib0017","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/bmt.2015.171","article-title":"Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases","volume":"50","author":"Slatter","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0018","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13352","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease","volume":"169","author":"Strocchio","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.014_bib0019","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705259","article-title":"Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)","volume":"37","author":"Kr\u00f6ger","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.014_bib0020","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","article-title":"Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial","volume":"96","author":"Ruutu","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.014_bib0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbmt.2016.11.023","article-title":"Survival advantage and comparable toxicity in reduced-toxicity treosulfan-based versus reduced-intensity busulfan-based conditioning regimen in myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation","volume":"23","author":"Sakellari","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.014_bib0022","doi-asserted-by":"crossref","first-page":"916.e1","DOI":"10.1016\/j.jtct.2021.07.020","article-title":"Survival advantage of treosulfan plus fludarabine before allogeneic hematopoietic cell transplantation for older or comorbid patients with myeloid malignancies","volume":"27","author":"Sakellari","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.014_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.17817","article-title":"Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT","volume":"195","author":"Shimoni","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2024.04.014_bib0024","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/bmt.2012.4","article-title":"Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity","volume":"47","author":"Shimoni","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0025","doi-asserted-by":"crossref","first-page":"428.e1","DOI":"10.1016\/j.jtct.2021.02.007","article-title":"Experience using anti-thymocyte globulin with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis in peripheral blood haploidentical stem cell transplantation","volume":"27","author":"Salas","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0026","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.02.001","article-title":"Improving safety and outcomes after allogeneic hematopoietic cell transplantation: a single-center experience","volume":"28","author":"Salas","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2024.04.014_bib0027","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1080\/10428194.2021.1966781","article-title":"Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections","volume":"62","author":"Salas","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.014_bib0028","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.014_bib0029","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"446","key":"10.1016\/j.jtct.2024.04.014_bib0030","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"10.1016\/j.jtct.2024.04.014_bib0031","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2024.04.014_bib0032","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the A cute L eukemia W orking P arty of the E uropean S ociety for B lood and M arrow T ransplantation","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2024.04.014_bib0033","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2014.01.009","article-title":"Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"20","author":"Gyurkocza","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.04.014_bib0034","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2017.12.785","article-title":"Transplant conditioning with treosulfan\/fludarabine with or without total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"24","author":"Deeg","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.04.014_bib0035","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41409-022-01830-3","volume":"57","author":"Gavriilaki","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.04.014_bib0036","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41409-023-02028-x","volume":"58","author":"Gavriilaki","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.014_bib0037","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.014_bib0038","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.bbmt.2020.04.021","article-title":"Less is more: superior graft-versus-host disease-free\/relapse-free survival with reduced-intensity conditioning and dual T cell depletion in acute myelogenous leukemia","volume":"26","author":"Salas","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.014_bib0039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000507536","article-title":"Post-transplant cyclophosphamide combined with anti-thymocyte globulin as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"144","author":"Alanazi","year":"2021","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.014_bib0040","doi-asserted-by":"crossref","first-page":"697.e1","DOI":"10.1016\/j.jtct.2023.08.009","article-title":"Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome","volume":"29","author":"Pereira","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.jtct.2024.04.014_bib0041","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","article-title":"Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy","volume":"15","author":"O'Donnell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"S1","key":"10.1016\/j.jtct.2024.04.014_bib0042","doi-asserted-by":"crossref","first-page":"e1830","DOI":"10.1002\/cnr2.1830","article-title":"Clinical outcomes of chemotherapy in cancer patients with different ethnicities","volume":"6","author":"Pathak","year":"2023","journal-title":"Cancer Rep."},{"issue":"11","key":"10.1016\/j.jtct.2024.04.014_bib0043","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1517\/17425255.2011.624513","article-title":"An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs","volume":"7","author":"Phan","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.014_bib0044","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/10781552211053248","article-title":"Retrospective assessment of chemotherapy\/biotherapy toxicity in a Hispanic\/Latinx population versus published study population","volume":"29","author":"Leidy","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.jtct.2024.04.014_bib0045","doi-asserted-by":"crossref","first-page":"181.e1","DOI":"10.1016\/j.jtct.2022.12.005","article-title":"Effect of CD34+ cell dose on the outcomes of allogeneic stem cell transplantation with post-transplantation cyclophosphamide","volume":"29","author":"Pedraza","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:17:43Z","timestamp":1751354263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724003671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666636724003671"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}